Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease

COMT (catechol-O-methyltransferase) inhibitors are key therapeutic agents in the management of motor fluctuations (MF) in patients with Parkinson’s disease (PD). As levodopa/DDCI add-on therapy, their main benefit lies in increasing ON-time and reducing OFF-time for PD patients in the middle stages...

Descripción completa

Detalles Bibliográficos
Autor principal: Jost, Wolfgang H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365060/
https://www.ncbi.nlm.nih.gov/pubmed/35968514
http://dx.doi.org/10.2147/NDT.S279362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365060/
https://www.ncbi.nlm.nih.gov/pubmed/35968514
http://dx.doi.org/10.2147/NDT.S279362

Ejemplares similares